![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Abstract
A male patient with primary AL amyloidosis who had been suffering from systemic lymphadenopathy with IgMκ-type M-proteinemia received two courses of VAD and high-dose melphalan with in vivo elimination of CD20+ cells using rituximab followed by autologous peripheral blood stem cell transplantation. Four years after complete hematological remission he showed marked reduction in size of the amyloid-laden lymph nodes. Deposits of AL amyloid may regress from the tissue if the chemotherapy succeeds in persistent inhibition of the production of an amyloidogenic immunoglobulin light chain.
| Abbreviations | ||
| VAD | = | vincristine, doxorubicin and dexamethasone |
| HDM | = | high-dose melphalan |
| SCT | = | autologous stem cell transplantation |
| CT | = | computed tomography |
| FLCs | = | free light chains |
| AL | = | amyloid derived from light chains |
| Abbreviations | ||
| VAD | = | vincristine, doxorubicin and dexamethasone |
| HDM | = | high-dose melphalan |
| SCT | = | autologous stem cell transplantation |
| CT | = | computed tomography |
| FLCs | = | free light chains |
| AL | = | amyloid derived from light chains |
Acknowledgements
This work was supported by a grant from the Intractable Disease Division, the Ministry of Health and Welfare, Amyloidosis Research Committee in Japan.